Intensity Therapeutics 在获得积极数据后，申请恢复乳腺癌研究的患者招募

关键事实

1Preliminary results showed 71.4% of patients receiving INT230-6 achieved a pathological complete response (pCR) compared to 33% in the standard of care arm.

2A 44% reduction in grade 3 or higher adverse events was observed in the INT230-6 cohort compared to the standard of care cohort.

Intensity Therapeutics (INTS) 已申请恢复其针对三阴性乳腺癌的2期INVINCIBLE-4研究的患者招募，此前该试验曾暂停。此举是在获得有前景的初步数据之后，数据显示71.4%接受INT230-6治疗的患者达到了病理完全缓解（pCR），显著优于标准治疗组33%的缓解率。该研究还显示出卓越的安全性，严重不良事件减少了44%。恢复招募标志着该公司推进其临床开发路径并寻求颠覆当前肿瘤治疗标准的关键一步。随着该公司利用这些强大的疗效和安全性信号，并解决试验的暂时暂停问题，市场情绪依然看涨。

社交热度

18/100

6 x 提及数

已丰富

免费注册以访问此内容

创建免费账户

版本历史

版本 115 days ago

变更内容: The story was updated to include the company's filing to resume patient enrollment in the INVINCIBLE-4 study after revealing the trial had been on a temporary pause.

来源: